News FDA Approves Tofidence (tocilizumab-bavi), a Biosimilar to Actemra September 29, 2023 Read More » OPFOLDA™ September 28, 2023 Read More » EXXUA September 28, 2023 Read More » Scynexis Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) Due to Potential for Cross Contamination with a Non Antibacterial ßlactam Drug Substance September 27, 2023 Read More » RYZUMVI™ September 27, 2023 Read More » LIKMEZ™ September 25, 2023 Read More » FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products September 20, 2023 Read More » FDA Approves First Therapeutic Indication for Revance’s Daxxify (daxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia September 20, 2023 Read More » First-line Treatment of Metastatic Castration-Resistant Prostate Cancer September 20, 2023 Read More » Page1 … Page8 Page9 Page10 Page11 Page12 … Page44 Benefit Advisors & Employees - Want to know more? Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager Full Name(Required) Email(Required) Comment(Required) Company Name(Required) CAPTCHA
Scynexis Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) Due to Potential for Cross Contamination with a Non Antibacterial ßlactam Drug Substance September 27, 2023 Read More »
FDA Approves First Therapeutic Indication for Revance’s Daxxify (daxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia September 20, 2023 Read More »
First-line Treatment of Metastatic Castration-Resistant Prostate Cancer September 20, 2023 Read More »